In the latest biosimilar business news, Fresenius Kabi announced a global partnership with Formycon for an ustekinumab biosimilar; Similis Bio partners with Novel351K to co-develop 3 biosimilars; and Celltrion Healthcare launched its bevacizumab biosimilar in Japan. Fresenius Kabi and Formycon Partnership Fresenius Kabi and Formycon announced that they will be partnering on an ustekinumab biosimilar (FYB202) referencing Stelara. Ustekinumab products are human monoclonal antibodies that target IL-12 and IL-23 for the treatment of moderate-to-severe plaque psoriasis, Crohn disease, ulcerative colitis, and psoriatic arthritis. “With the commercialization of the ustekinumab biosimilar we are expanding our product portfolio with another autoimmune disease treatment option…" commented Michael Schönhofen, PhD, Fresenius Kabi’s chief operating officer and member of the Fresenius Kabi Management Board, in a statement. "We welcome the potential of this agreement to build on the strengths of our companies across the value chain from development to commercialization." The licensing agreement will grant Fresenius Kabi exclusive commercialization rights to FYB202 in key global markets, including Germany as well as parts of the Middle East and Northern Africa Region and Latin America. Formycon will be in charge of development and registration with health authorities. Formycon will also receive upfront and milestone payments contingent […]
Click here to view original web page at www.centerforbiosimilars.com
